Mine Karadeniz

Mine Karadeniz

Auto-generated profile, based on publicly available information

Mine Karadeniz

Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
ÖAözge özcan abacıoğlu
özge özcan abacıoğlu
ATAdana- Turkey
Adana- Turkey
AYArafat Yildirim
Arafat Yildirim
NKNermin Yıldız Koyunsever
Nermin Yıldız Koyunsever
MKMine Karadeniz
Mine Karadeniz
SKSalih Kılıç
Salih Kılıç
Stent thrombosis (ST) is an uncommon but serious complication in patients undergoing percutaneous coronary intervention (PCI). This study aimed to investigate the effect of atherogenic index of plasma (AIP) on ST. Among the 10,258 patients who underwent coronary angiography between January 2018 and December 2020, 239 patients who underwent PCI with the diagnosis of acute coronary syndrome (ACS) due to ST were included as the study group (ST group) and 459 patients who underwent percutaneous intervention for ACS and did not have any in-stent lesion as the control group (non-ST group). ST classification was done according to the Academic Research Consortium definition. The mean age of the patients was 63.3±10.6 years (483 male, 69.2%). The groups were similar in terms of characteristic properties, comorbidities, and the drugs being used (p>0.05 for all). Drug eluting stents were used in 86.5% of the patients. In the ST group, the median time from stent implantation to thrombosis was 285 days. Mean AIP and the ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) were statistically significantly higher in the ST group than in the controls (p<0.001 and p=0.018, respectively), and a positive correlation was observed between time from stent implantation to thrombosis and AIP and TG/HDL-C (rS=0.229, p=0.010 and rS=0.222, p=0.010, respectively). Multivariate logistic regression analysis revealed that stent length, prior ST elevation myocardial infarction, TG/HDL-C, and AIP were independent predictors of ST. AIP is an easy calculable biomarker, and the performance of AIP to predict ST is better than TG/HDL-C.

22 September 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
MYMurat Yıldırım
Murat Yıldırım
BEBatuhan Erdoğdu
Batuhan Erdoğdu
SSSelim Sayın
Selim Sayın
OKOzan Kaplan
Ozan Kaplan
EKEmine Koc
Emine Koc
MAMELTEM Ayli
MELTEM Ayli
Background/Objectives: The differential diagnosis between primary polycythemia vera (PV) and secondary polycythemia (SP) presents significant clinical challenges owing to substantial phenotypic overlap. This investigation utilized untargeted metabolomic approaches to elucidate disease-specific metabolic perturbations and evaluate the metabolic consequences of cytoreductive therapeutic interventions. Methods: Plasma specimens obtained from PV patients (n = 40) and SP patients (n = 25) underwent comprehensive metabolomic profiling utilizing liquid chromatography–mass spectrometry (LC-MS) platforms. Multivariate statistical analyses, including principal component analysis (PCA), were employed in conjunction with pathway enrichment analyses to characterize disease-associated metabolic dysregulation. Additionally, receiving treatment (tPV) (n = 25) and not receiving treatment (ntPV) (n = 15) PV patients were compared to assess therapeutic metabolic effects. Results: Comprehensive metabolomic analysis identified 67 significantly altered metabolites between PV and SP patients, with 36 upregulated and 31 downregulated in PV. Key upregulated metabolites in PV included thyrotropin-releasing hormone, 3-sulfinoalanine, nicotinic acid adenine dinucleotide, and protoporphyrin IX, while 4-hydroxyretinoic acid and deoxyuridine were notably downregulated. Pathway enrichment analysis revealed disruptions in taurine, glutamate, nicotinate, and cysteine metabolism in PV. ntPV patients exhibited higher glucose and octanoyl-CoA levels compared to treated patients, indicating the normalization of glucose and fatty acid metabolism with cytoreductive therapy. ntPV was also associated with altered B-vitamin metabolism, including decreased nicotinic acid adenine dinucleotide and increased nicotinamide ribotide levels. Cross-comparison analysis revealed overlapping pathway enrichment in glutamate metabolism, nicotinate and nicotinamide metabolism, and cysteine metabolism between both comparisons. Conclusions: This study demonstrates that PV and SP exhibit fundamentally distinct metabolic signatures, providing novel insights into disease pathogenesis and potential diagnostic biomarkers. The identification of oxidative stress signatures, disrupted energy metabolism, and altered B-vitamin cofactor pathways distinguishes PV from SP at the molecular level. Cytoreductive therapy significantly normalizes metabolic dysregulation, particularly glucose and nucleotide metabolism, validating current therapeutic approaches while revealing broader systemic treatment effects. The metabolic signatures identified, particularly the combination of deoxyuridine, thyrotropin-releasing hormone, and oxidative stress metabolites, may serve as complementary diagnostic tools to traditional morphological and molecular approaches. These findings advance our understanding of myeloproliferative neoplasm pathophysiology and provide a foundation for developing metabolically targeted therapeutic strategies and precision medicine approaches in PV management.

29 April 2023 in DAHUDER Medical Journal
Verified
Journal Article
Open access
PDF file
MKMine Karadeni̇z
Mine Karadeni̇z
ÖAözge özcan abacıoğlu
özge özcan abacıoğlu
UMUmit Yavuz Malkan
Umit Yavuz Malkan
İHİbrahim Celalettin Haznedaroğlu
İbrahim Celalettin Haznedaroğlu
Objectives: Chronic myeloproliferative diseases (CMPD) are neoplastic disorders leading to hypercoagulability and thrombosis. The critical hemostatic abnormalities include alterations in the blood viscosity and a history of recent thrombus. The aim of this study is to assess the interrelationships among the atherogenic index of plasma (AIP) and thromboembolism of CMPD with JAK2 V617F mutation. Methods: Ninety-two patients diagnosed as CMPD with JAK2 V617F mutation and 73 controls were included into the study. The patients were evaluated for the presence of any venous or arterial thromboembolic events. AIP was calculated by using the formula log (Tg/HDL) from serum triglyceride and high-density lipoprotein values. Results: The study group consisted of 30 patients (33%) with myelofibrosis (MF), 42 patients (46%) with polycythemia vera (PV) and 20 patients (21%) with essential thrombocythemia (ET). Two study groups were similar in terms of sex, age and other comorbidities (p > 0.05). CMPD group had higher levels of right blood cell count (RBC), red blood cell distribution width (RDW), platelets (PLT), hemotocrit (Hct) and AIP. Univariate and multivariate logistic regression analysis revealed that platelet count, RBC and AIP were independent predictors for thrombosis in both groups. The comparison of ROC curve analysis disclosed that AIP was superior to platelet count and RBC in predicting thrombosis. Conclusion: AIP can be used to determinate higher risk of thromboembolism in patients with CMPD. As a reliable and ‘easy-to-assess’ diagnostic tool, AIP could be useful for the determination of thrombotic events in CMPD clinicobiological disease course.

29 March 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MKMine Karadeniz
Mine Karadeniz
OÇOlgu Erkin Çınar
Olgu Erkin Çınar
BEBatuhan Erdoğdu
Batuhan Erdoğdu
UMUmit Yavuz Malkan
Umit Yavuz Malkan
HGHakan Goker
Hakan Goker
OOOsman Ilhami Ozcebe
Osman Ilhami Ozcebe
Introduction: Tyrosine kinase inhibitors (TKis) and Bruton's TKi (BTKis) constitute broadly used antitumor drug groups with almost completely tolerable and manageable side-effect profiles. Mainly side effects are cardiovascular and gastrointestinal for the TKi group. Hypophosphatemia is documented frequently in many studies with TKis but rarely mentioned with ibrutinib use up to the present. Case report: A 61-year-old patient with the diagnosis of chronic lymphocytic leukemia had hypophosphatemia-related complaints and symptoms when ibrutinib use was preferred for his second relapse of the disease. After drug discontinuation, we started ibrutinib again with an alternating dose. We managed to control hypophosphatemia, and the patient has been following up for 2 years in remission status without any support or a second drug need. Management and outcome: We have presented here a chronic lymphocytic leukemia case that developed mild–severe hypophosphatemia associated with ibrutinib use. By using an alternating dose of ibrutinib, we managed to control the disease and drug side effects. Discussion: TKis and BTKis are widely in use for different indications. Hypophosphatemia is rare but it can cause drug discontinuation or change if it is not manageable. It is mentioned that hypophosphatemia can be seen due to a common group effect with the mechanism of causing secondary hyperparathyroidism and renal tubulopathy. In our case, we could explain the side effect of hypophosphatemia with secondary hyperparathyroidism and renal tubulopathy. Prospective, large-group studies are needed to explain the hypophosphatemia and other side effects of ibrutinib and new BTKis in detail.

30 March 2023 in European Journal of Therapeutics
Verified
Journal Article
Open access
PDF file
ÖAözge özcan abacıoğlu
özge özcan abacıoğlu
AYArafat Yildirim
Arafat Yildirim
MKMine Karadeniz
Mine Karadeniz
AAArmagan Acele
Armagan Acele
FDFerhat Dindas
Ferhat Dindas
IKİbRahim Halil Kurt
İbRahim Halil Kurt
Objective: to evaluate CANLPH score and systemic immune inflammation index (SII) in patients with symptomatic rheumatic mitral stenosis (MS) undergoing percutaneous mitral balloon valvuloplasty (PMBV). Methods: 62 patients who underwent PMBV in our clinic between 2018 and 2021 were included retrospectively. The patients were divided into 2 groups according to echo score. The CANLPH score was calculated from the cut-off values of C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR) and platelet to hemoglobin ratio (PHR), determined with the Youden index and SII by the formula platelet x neutrophil/lymphocyte. P 8 group (p <0.001, both). The mean mitral gradient before and after PMBV was 12.6±5.7mm Hg and 5.0±2.4 mm Hg, and the mean valve area was 1.12±0.27 cm2 and 1.85±0.29 cm2. A statistically significant and negative correlation was observed between the gradient decrease after the procedure and the CANLPH score and SII (r=-0.426, p=0.001 and r=-0.418, p=0.001, respectively). In receiver operating characteristic (ROC) curve analysis, it was concluded that the ability of CANPLH score to predict the higher Echo scores was noninferior to SII with an area under curve (AUC:0.820 (0.701-0.906) and AUC:0.786 (0.664-0.880), z statistics 0.576 and p=0.564. Conclusion: SII and CANLPH scores are correlated with Echo score. A significant negative relationship was found with both biomarkers and gradient decrease after the PMBV.

10 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
BEBatuhan Erdoğdu
Batuhan Erdoğdu
DGDuygu Gül
Duygu Gül
BABerrak Itır Aylı
Berrak Itır Aylı
MKMine Karadeniz
Mine Karadeniz
MYMurat Yıldırım
Murat Yıldırım
MCMelike Cömert
Melike Cömert
Background: Multiple myeloma (MM) diagnosis requires specialised testing that is not universally available, contributing to diagnostic delays. The aim of this study was to develop and internally validate statistical and machine learning (ML) models that discriminate MM from clinically similar conditions using exclusively routine laboratory parameters. Methods: This retrospective diagnostic prediction model study included 422 consecutive patients referred to hematology for suspected MM at a tertiary care center (2017–2025). Fifteen routine demographic and laboratory variables were used to train seven ML algorithms and two ensemble methods. Model performance was evaluated on a held-out test set (30%) using the area under the receiver operating characteristic curve (AUC) with bootstrap 95% confidence intervals, calibration metrics, and decision curve analysis. Internal validation comprised repeated 10-fold cross-validation and bootstrap optimism correction (1000 resamples). Results: Of 422 patients, 203 (48.1%) were diagnosed with MM. Random Forest, Gradient Boosting, and Ensemble Stacking showed similarly high discrimination on the test set (AUCs 0.950–0.955). Total protein (multivariable-adjusted OR: 11.95), calcium (OR: 9.62), hemoglobin (OR: 4.34), and albumin (OR: 0.16) were the strongest independent predictors. Ensemble Stacking showed the best calibration (Brier score 0.084; calibration slope 1.14). At a ≥95% sensitivity threshold, Random Forest maintained 77.3% specificity. Risk stratification effectively separated patients, with observed MM rates ranging from 2.4% (very low risk) to 97.2% (very high risk). Conclusions: Machine learning models using routine laboratory parameters achieved excellent diagnostic performance for discriminating MM from its clinical mimickers in a real-world referral cohort. Following further development with larger datasets and external validation, these models could support triage and prioritization of patients already under evaluation for suspected MM, particularly where access to specialized testing is delayed; use in lower-prevalence, first-contact settings would require recalibration and dedicated validation.